Nanochromium Citrate: Antihyperglycemic and Pancreatoprotective Action Against Underlying Dexamethasone-Induced Diabetes Mellitus

Abstract

INTRODUCTION: The Ukrainian State Scientific-Research Institute of Nanobiotechnology and Resources Saving has received nanochromium citrate (NCC), a new chrome compound, by means of the electric pulse aquananotechnology method.
 
 OBJECTIVES: to determine nanochromium citrate efficacy with experimental dexamethasone-induced diabetes through the results of antihyperglycemic activity and its effect on the pancreatic histological structure.
 
 METHODS: diabetes mellitus was simulated by dexamethasone administration on 18-month male rats. The morphological structure of the pancreas was examined in comparison with metformin. Examination of the pancreas morphological structure considered the amount, distribution and size of the pancreatic islets and their cellular shape.
 
 RESULTS: on the 14th day of simulated diabetes mellitus the preventitive -therapeutic indication of nanochromium citrate promoted a decrease of glycemia level twice. The administration of nanochromium citrate with underlying diabetes mellitus is not inferior to metformin and its protective effect on the pancreas morphological structure exceeds the effect of metformin.
 
 CONCLUSION: nanochromium citrate of experimental dexamethasone-induced diabetes mellitus in rats decreases the glycemia level twice which does not differ reliably from the effect of metformin antihyperglycemic. The cytoprotective effect of nanochromium citrate produced on the histological structure of the pancreas is found to exceed metformin action.